|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 65 Hayden Avenue |
Address2 | |
City | Lexington |
State | MA |
Zip Code | 02421 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 40026226-75
|
||||||||
|
6. House ID# 398750000
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mark T. Battaglini, Esq., Vice President, Government Affairs |
Date | 10/20/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Settlements of patent litigation between innovator drug companies and generic drug companies. (S.369 and H.R. 1760)
Comprehensive Reform of Current patent law (H.R. 1260 and S.515)
S. 610 Patent Reform Act of 2009 - changes to drug patent litigation issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Medical Research
Antibiotic Resistance issues
P.L. 111-148 Patient Protection and Affordable Care Act (PPACA) - funding of PPACA programs and provisions
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
PDUFA Reauthorization - The Prescription Drug User Fee Act is due for reauthorization in 2012 and discussions in anticipation of that reauthorization have begun
H.R. 5712 Health Care Technical Corrections - This bill would repeal a provision of the health care reform bill that would extend debarring to all parts of a corporate family when any part of that corporate family settles an investigation of misconduct with the government
HR 759 Food and Drug Administration Globalization Act of 2009
S. 882 The Drug and Device Accountability Act of 2009
H.R.5740 - To provide for the mandatory recall of adulterated or misbranded drugs
S. 369 Preserve Access to Affordable Generics Act
H.R. 1706 Protecting Consumer Access to Generic Drugs Act
H.R. 573 Fair Prescription Drug Competition Act
S. 501 Fair Prescription Drug Competition Act
H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) - changes to the 340B Drug Discount Program.
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Coverage Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) - changes to the 340B Drug Discount Program.
P.L. 111-148 Patient Protection and Affordable Care Act (PPACA) - funding of PPACA programs and provisions
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
S. Amdt. (Baucus) to H.R. 4849 Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions)
H.R. 1586 Education Jobs and Medicaid Funding Bill (Average Manufacturer Price - AMP Revisions)
H.R. 4899 Supplemental Appropriations Act, 2010 (Average Manufacturer Price - AMP Revisions and "Pay to Delay" Provision)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provisions)
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
P.L. 111-148 Patient Protection and Affordable Care Act (PPACA) - funding of PPACA programs and provisions
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital and "Pay to Delay" Provision)
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) - changes to the 340B Drug Discount Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R. 2400 Strategies to Address Antimicrobial Resistance Act (STAAR)
H.R. 2937 Methicillin Resistant Staph Aureus (MRSA) Infection Prevention and Patient Protection Act
S. 369 Preserve Access to Affordable Generics Act of 2009
H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq, |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Antibiotic resistance and wounded troops
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |